Literature DB >> 18353622

A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma.

Jie Ge1, Zhikang Chen, Shaobin Wu, Weijie Yuan, Bin Hu, Zihua Chen.   

Abstract

AIMS: To analyse the clinicopathological characteristics of the expression of cadherin-17 (CDH17) and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma, and to evaluate the clinical significance of these two markers in the histological classification and prognosis of gastric carcinoma.
MATERIALS AND METHODS: CDH17, CDX2 protein expression in paraffin-embedded specimens gathered from 166 patients with gastric carcinoma were detected by immunohistochemistry. The association of CDH17, CDX2 protein expression with the clinicopathological characteristics, and with the prognosis of gastric carcinoma were subsequently assessed.
RESULTS: CDH17, nucleus and cytoplasm CDX2 expression were positively expressed in 101/166 (60.8%), 59/166 (35.5%) and 57/166 (34.3%) gastric carcinoma patients, respectively. The expression of both CDH17 and CDX2 is associated with the intestinal-type gastric carcinoma (P<0.01). Positive expression of CDH17 was significantly associated with the depth of gastric wall invasion (P=0.04), lymph node metastasis (P<0.01) and stages of gastric carcinoma (P=0.01). Positive expression of CDX2 in the nucleus was mainly found in male patients (P=0.02), in early stage (P=0.01) and medullary-type gastric carcinoma (P=0.02). There was a negative association between nuclear CDX2 expression and lymph node metastasis of gastric carcinoma (P<0.01). The combined expression of CDH17 and CDX2 was significantly lower in diffuse-type carcinoma than intestinal- or mixed-type carcinoma (P<0.01 and P=0.01, respectively). The patients with CDH17 expression associated with poor prognosis of gastric carcinoma (P<0.01), as opposed to patients with CDX2 expression (P<0.01). The survival rate of patients with CDH17+/CDX2- expression was the lowest (P<0.01), and conjoined expressions of CDH17+/CDX2- and CDH17+/CDX2+ were independent prognostic indicators of gastric carcinoma (both P<0.01).
CONCLUSION: The results suggest that the expression of CDH17 or CDX2 may be an important feature of gastric carcinoma. A combined detection of CDH17/CDX2 co-expression may benefit us in predicting the prognosis of gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353622     DOI: 10.1016/j.clon.2008.01.013

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  16 in total

1.  CDX2 as a marker for intestinal differentiation: Its utility and limitations.

Authors:  Reda S Saad; Zeina Ghorab; Mahmoud A Khalifa; Mei Xu
Journal:  World J Gastrointest Surg       Date:  2011-11-27

Review 2.  Association between cadherin-17 expression and pathological characteristics of gastric cancer: a meta-analysis.

Authors:  Zi-Wen Long; Meng-Long Zhou; Jing-Wei Fu; Xian-Qun Chu; Ya-Nong Wang
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

3.  Simultaneous amperometric immunosensing of the metastasis-related biomarkers IL-13Rα2 and CDH-17 by using grafted screen-printed electrodes and a composite prepared from quantum dots and carbon nanotubes for signal amplification.

Authors:  Verónica Serafín; Alejandro Valverde; María Garranzo-Asensio; Rodrigo Barderas; Susana Campuzano; Paloma Yáñez-Sedeño; José M Pingarrón
Journal:  Mikrochim Acta       Date:  2019-06-10       Impact factor: 5.833

4.  Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer.

Authors:  Hyuk-Joon Lee; Ki Taek Nam; Heae Surng Park; Min A Kim; Bonnie J Lafleur; Hiroyuki Aburatani; Han-Kwang Yang; Woo Ho Kim; James R Goldenring
Journal:  Gastroenterology       Date:  2010-04-13       Impact factor: 22.682

5.  CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancer.

Authors:  Motonobu Saito; Hirokazu Okayama; Katsuharu Saito; Jin Ando; Kensuke Kumamoto; Izumi Nakamura; Shinji Ohki; Yoshimasa Ishi; Seiichi Takenoshita
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

Review 6.  New insights into the functions and localization of the homeotic gene CDX2 in gastric cancer.

Authors:  Lin-Hai Yan; Wei-Yuan Wei; Yu-Bo Xie; Qiang Xiao
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

7.  Prognostic significance of Cdx2 immunohistochemical expression in gastric cancer: a meta-analysis of published literatures.

Authors:  Xiao-Tong Wang; Wei-Yuan Wei; Fan-Biao Kong; Chao Lian; Wen Luo; Qiang Xiao; Yu-Bo Xie
Journal:  J Exp Clin Cancer Res       Date:  2012-11-26

8.  Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma.

Authors:  Ling Xiao Liu; Nikki P Lee; Vivian W Chan; Wen Xue; Lars Zender; Chunsheng Zhang; Mao Mao; Hongyue Dai; Xiao Lin Wang; Michelle Z Xu; Terence K Lee; Irene O Ng; Yangchao Chen; Hsiang-fu Kung; Scott W Lowe; Ronnie T P Poon; Jian Hua Wang; John M Luk
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

9.  Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling.

Authors:  Hai-bo Qiu; Li-yi Zhang; Chao Ren; Zhao-lei Zeng; Wen-jing Wu; Hui-yan Luo; Zhi-wei Zhou; Rui-hua Xu
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

Review 10.  Possible roles of LI-Cadherin in the formation and maintenance of the intestinal epithelial barrier.

Authors:  Werner Baumgartner
Journal:  Tissue Barriers       Date:  2013-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.